TRIUMPH-3 (80 weeks, 12mg, 1,949 patients with cardiovascular disease): 22.6% weight loss
1), each conducted at single sites (Parexel International, Harrow, UK, and Parexel International GmbH, Berlin, Germany, respectively)
It means the access pathway, safety data, labeling, and monitoring expectations differ
The molecule is identical, and 503B facilities operate under Current Good Manufacturing Practice (CGMP) standards enforced by the FDA
For patients who prefer to skip injections, who travel often, dislike needles, or want a more discreet routine, the oral tablet form provides a daily dosing option with the same active mechanism